Clinical Trial Update: Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluates the combination of ibrutinib and brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. The study has completed and results h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Adcetris (Brentuximab vedotin)
• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2023-07-10